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Background: Breast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening is
available, there is an ongoing interest in improved early detection and prognosis. Herein, we have analysed a combination of
serological biomarkers in a case–control cohort of sera taken before diagnosis.
Methods: This nested case–control study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) used serum
samples from 239 women who subsequently developed breast cancer and 239 matched cancer-free controls. Sera were screened
by ELISA for 9 candidate markers. Univariate and multivariate analyses were performed to examine associations with clinico-
pathological features and between case controls in different time groups before diagnosis.
Results: Significant associations with clinico-pathological features related to prognosis were found for several candidates (CA15-3,
HSP90A and PAI-1). However, there were no consistent differences between cases and controls for any candidate in the lead up to
diagnosis. Whilst combination models outperformed single markers, there was no increase in performance towards diagnosis.
Conclusions: This study using unique pre-diagnosis samples shows that CA15-3, HSP90A and PAI-1 have potential as early
prognostic markers and warrant further investigation. However, none of the candidates or combinations would be useful for
screening.
Breast cancer is the most common neoplasm in women and the
second leading cause of cancer-related mortality in females
worldwide (Siegel et al, 2014). At present, breast cancer detection
relies mostly on mammography, which has been associated with
decreased breast cancer mortality (Jatoi, 1999; Gotzsche and
Jorgensen, 2013). However, mammography screening has gener-
ated controversy due to the risks of false-positive results and over-
diagnosis of indolent disease (Baum, 2010; Gotzsche and
Jorgensen, 2013; Pace and Keating, 2014; Welch et al, 2016).
Mammography also has limited sensitivity for the detection of
tumours in dense breast tissue (Boyd et al, 2007). There is thus an
urgent need for early biomarkers that could predict disease
outcome, providing prognostic information to the clinician for
treatment stratification. The addition of a blood-based tumour
marker test may also increase patient compliance as blood testing
is more acceptable and would also circumvent the problems
associated with imaging high-density breast tissue.
Some blood-borne tumour markers have demonstrated ability
to detect malignancy before clinical diagnosis and are currently
being evaluated in screening trials for certain cancers; for example,
CA125 for screening ovarian cancer (Menon et al, 2015). Breast
cancer markers in clinical practice are used for predicting response
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to therapy, monitoring after primary therapy or as prognostic
indicators (Harris et al, 2007). However, there are currently no
blood-borne biomarkers recommended for breast cancer diagnosis
or screening. Although candidate markers such as carcinoem-
bryonic antigen (CEA), the soluble form of MUC1 protein (CA15-
3, CA27.29) and circulating cytokeratin fragments (TPA, TPS and
CYFRA 21-1) have been suggested as diagnostic markers, they lack
sensitivity for early disease detection and/or lack specificity.
Almost all diagnostic biomarker studies to date have used
samples collected at or just after diagnosis and therefore may be
confounded by late-stage responses to advanced tumours. Ideally,
samples taken before clinical diagnosis should be used in the search
for biomarkers of pre-symptomatic, early stage disease and for
predicting prognosis. Herein, we have sourced such pre-diagnostic
samples from the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS); a multi-centre RCT (the largest ever
undertaken), which aims to assess if screening for ovarian cancer
can save lives (Menon et al, 2009, 2015). Serum samples were taken
from 239 UKCTOCS women who were diagnosed with invasive
ductal carcinoma of the breast, months to years after sample
donation. Cases were matched 1 : 1 with samples from non-cancer
controls. The serum biomarkers investigated in this study were
chosen based on previous evidence of their potential as serum and/
or tissue markers of breast cancer: CA15-3 (cancer antigen 15-3)
(Hayes et al, 1986; Geraghty et al, 1992; Stieber et al, 2003),
RANTES/CCL5 (regulated on activation, normal T cell expressed
and secreted/chemokine (C–C motif) ligand 5) (Soria and
Ben-Baruch, 2008; Gonzalez et al, 2011), OPN (osteopontin)
(Singhal et al, 1997; Fedarko et al, 2001; Bramwell et al, 2014),
PAI-1 (plasminogen activator inhibitor-1; Harris et al, 2007; Duffy
et al, 2014), SLPI (secretory leukocyte protease inhibitor) (Hu et al,
2004; Bouchard et al, 2006), HSP90A (heat shock protein 90A;
Pick et al, 2007; Duran et al, 2008; Cheng et al, 2012), IGFBP3
(insulin-like growth factor-binding protein 3; McCarthy et al, 2009;
Worthington et al, 2010), APOC1 (apolipoprotein C-I)
(Opstal-van Winden et al, 2011; Devetyarov et al, 2012; Chung
et al, 2014; Lee et al, 2015) and PAPPA (pappalysin-1; Loddo et al,
2014; Mansfield et al, 2014). Herein we report on the ability of
these serum markers to detect breast cancer cases before their
diagnosis and examine associations with clinico-pathological
features and prognostic indicators.
MATERIALS AND METHODS
Ethics, consent and permissions. UKCTOCS participants gave
informed written consent at recruitment for the use of their
medical notes and serum in ethically approved secondary studies
(UK North West Medical Research and Ethics Committee (MREC
00/8/34)). Ethical approval for this nested case–control study was
granted by The Joint UCL/UCLH Committees on the Ethics of
Human Research (Committee A) REC ref 05/Q0505/57.
Subjects. UKCTOCS participants were post-menopausal women
aged 50–74, who had no active malignancy at recruitment (Menon
et al, 2008). Notifications of women subsequently diagnosed with
invasive ductal carcinoma of the breast were retrieved by querying
the Health and Social Care Information Centre (HSCIC) cancer
and death registries with the International Classification of
Diseases code C50 pertaining to malignant neoplasms of the
breast. Cancer notifications were also received via self-reported
data completed 3.5 years post-randomisation to the UKCTOCS.
Breast cancer notifications were confirmed and characterised by
postal questionnaire sent to treating clinicians (consultant, or
General Practitioner if details not provided by the volunteer),
which was designed to ascertain clinical and histological data on
diagnosed cases (date of diagnosis, histology, nodal status, staging,
grade, prognosis, ER, PR and HER2 status). Staging for each case
was determined using the TNM system, taking into account tumour
size (T), spread to the lymph nodes (N), and whether the tumour
had metastasised (M). To provide an indication of prognosis, the
Nottingham prognostic index (NPI) was calculated for each case
using the formula [0.2 S]þNþG, where S¼ tumour size in cm,
N¼ node status (0 nodes¼ 1, 1–4 nodes¼ 2, 44 nodes¼ 3) and
G¼ numerical grade. Cases were stratified into good and poor
prognosis using an NPI p4 and 44, respectively. Controls were
age-matched and were women from the same trial centre who had
no history of cancer, and who had donated serum samples on the
same date as the matched case. Characteristics of the case–control
set are shown in Table 1. There was no significant difference in time
to spin (clotting time) or age between cases and controls.
Samples and assays. Blood was collected and serum prepared
according to a standardised protocol within the UKCTOCS
(Menon et al, 2009) and then shipped frozen to a cryo-repository
for long-term storage in liquid nitrogen. For the study, single
samples from cases were selected that predated diagnosis by a
median time of 1.15 years (13.8 months; range 0.1–53.8 months).
Samples were retrieved from storage and shipped to the laboratory
on dry ice and thawed at 4 1C for random aliquoting before assay.
Serum concentrations of all biomarker candidates were measured
using commercial enzyme-linked immunosorbent assays (ELISA)
according to the manufacturers’ instructions. Optimum serum
dilutions were first determined using a pool of serum from cases
and controls and used to determine inter-assay CVs. The ELISA
kits used, dilutions and inter-assay CVs were; CA15-3 (Human)
ELISA kit (Abnova; 1 : 50; 7.3%), Human CCL5/RANTES Quanti-
kine ELISA (R&D; 1 : 100; 8.1%), Human IGFBP-3 Quantikine
ELISA (R&D; 1 : 100; 9.8%), Human PAI-1 ELISA Kit (Invitrogen;
1 : 25; 8.1%), Human Osteopontin (OPN) Quantikine ELISA
(R&D; 1 : 12.5; 6.1%), Hsp90a ELISA Kit (Stressgen; 1 : 30; 6.5%),
Human SLPI Quantikine ELISA (R&D; 1 : 30; 8.5%), human
Pappalysin-1 (PAPPA) ELISA kit (DRG; 1 : 200; 11.3%) and
human Apolipoprotein C-I (APOC1) ELISA kit (Abnova; 1 : 100;
11.1%). There were no strong correlations with clotting time or
volunteer age for any of the measured analytes.
Statistical analysis. Univariate analysis using GraphPad Prism
software (v5.01) was used to test associations between analyte
measurements and clinico-pathological features and between cases
and matched controls in different time groups before diagnosis.
For normally distributed data, the Student t-test was used to assess
significance of differences; otherwise the Mann–Whitney U-test
was used. P-values of o0.05 were considered significant. Kaplan–
Meier analysis was used to examine biomarker levels in relation to
survival in cases using time from sample collection to death and
various candidate marker cut-off values. The log-rank test was used
to test significance between the survival curves. Multivariate
logistic regression models were constructed and tested within the R
environment (v3.1.1 for Mac OS). Evaluation of performance of
each model was based on receiver operating characteristic (ROC)
curve analysis, with determination of significance of differences in
areas under the curves using the method of DeLong et al (1988). A
modelling approach based on the neuro-fuzzy technique was also
applied to the data, which combines the mathematical construc-
tions of fuzzy logic (Nauck et al, 1997; Paiva and Dourado, 2004)
and neural networks. Briefly, a fuzzy model was generated using
half of the data and its parameters estimated to minimise the
difference between the model and the experimental data. Model
adjustment was based on the sub-gradient modification method for
the case of undifferentiated functions, the so-called r-algorithms by
Shor (Kiseleva and Shor, 2005), with an accuracy of e¼ 0.001. The
model was then validated on the other half of the data. Software
implementation of the approach was developed within the Visual
Cþþ environment.
2 www.bjcancer.com |DOI:10.1038/bjc.2016.433
BRITISH JOURNAL OF CANCER Early detection and prognosis of breast cancer
RESULTS
Pre-diagnostic candidate marker levels in discrimination of
case–control samples. In this UKCTOCS nested case–control set,
volunteers donated serum up to 5 years before clinical diagnosis of
breast cancer, with a median time to diagnosis of 1.15 years (13.8
months). We hypothesised that serum levels of the candidate
markers may be altered in women with a clinically undetectable
tumour. Initially, biomarker data from all case samples were
compared with all non-cancer controls and then those taken less
than and greater than the median time to diagnosis. No single
candidate marker showed a significant difference between cases
and controls for these comparisons. Samples were also stratified
into time groups that came from cases who developed breast
cancer within 0.5 years, 0.5–1 years, 1–2 years, 2–3 years and 3–5
years of sample collection and candidate marker levels were
compared against matched-control samples for these groups.
Overall, there were no consistent changes in serum concentrations
for any marker in cases in the lead up to diagnosis, although some
significant differences between cases and controls were apparent
for some candidates in different time groups. Thus, cases had
elevated levels of IGFBP3 (P¼ 0.044) 0–0.5 years before diagnosis,
lower levels of RANTES (P¼ 0.013) 2–3 years before diagnosis and
higher levels of APOC1 (P¼ 0.011) and lower levels of PAPPA
(P¼ 0.036) at 3–5 years before diagnosis.
Combining markers (including age as a parameter) using
logistic regression failed to provide accurate discrimination of cases
and controls in any pre-diagnosis time group, although combined
models performed better than the single markers for classification
(Table 2). There was no trend of improved classification in the lead
up to diagnosis and sensitivities were in the range 4–26% at a
specificity of 495%. A novel modelling approach based on the
neuro-fuzzy technique also failed to provide accurate models, with
sensitivities in the range 10–27% (data not shown). These data
suggest that these candidates alone or combination are not accurate
markers for predicting breast cancer.
Pre-diagnostic candidate marker levels in relation to
clinico-pathological features. Pre-diagnostic serum levels of
CA15-3 were significantly raised in samples from late-stage cases
(stages 3/4 combined) vs controls and stage 1 and stage 2 cases
(Tables 3A and 4; Figure 1A) and with node positivity within cases
(Table 4). The marker was also raised significantly in node positive
cancers within cases (Table 4) and vs controls in the subset of cases
from which samples were taken o1.15 years before clinical
diagnosis (Table 3B). However, CA15.3 levels were lower in grade 1
cancers vs controls or grade 2 cancers. Neither RANTES or OPN
Table 1. Study set and clinico-pathological features
Variable Cases Controls P-value
No. individuals 239 239
No. samples 239 239
Mean time to spin (h; range) 24.05 (1.83–47.69) 23.87 (1.77–47.78) 0.52
Mean age at sample draw (years; range) 61.24 (50.6–75.9) 60.78 (50.3–76.5) 0.3
Median time from sample draw to diagnosis (months; range) 13.84 (0.13–53.81)
Tumour grade (number of cases)
1 47
2 111
3 81
Node status (number of cases)
N0 176
N1 63
Stage (number of cases)
1 115
2 87
3 12
4 2
Not assessed 23
Metastasis (number of cases)
M0 166
M1 2
Not assessed (Mx) 28
Not available 43
NPI estimate (number of cases)
p4.0 107
44.0 96
Not available 36
HER2 status (number of cases)
Negative 136
Positive 47
Not available 56
ER status (number of cases)
Negative 47
Positive 191
Unknown 1
PR status (number of cases)
Negative 84
Positive 132
Not available 23
Abbreviation: NPI¼Nottingham prognostic index.
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discriminated cases from controls for any of the pathological
parameters examined (Table 3), and whereas altered levels of both
were associated with tumour stage at diagnosis within cases
(Table 4), for RANTES, this was not seen in the o1.15 year to
diagnosis group and for OPN, the changes were not consistent,
with lower levels in stage 2 vs stage 1 or stage 3/4 cases. IGFBP3
also failed to discriminate cases from controls, although was
decreased in case samples that went on to be diagnosed with
HER2þ breast cancer where there was a strong association for the
o1.15 years to diagnosis group (Table 4B; Figure 1B). Serum levels
of PAI-1 were significantly lower in samples from women who
went on to be diagnosed with grade 3 cancer vs controls and grade
2 cancers and within cases with a higher NPI (Figures 1C and D).
Similarly, HSP90A levels were lower in pre-diagnosis serum of
grade 3 cases vs controls and in cases with a higher NPI (Figures 1E
and F,) with the differences more significant closer to diagnosis
(Tables 3 and 4). The association of lowered HSP90A with
prognostic index was also significant (P¼ 0.012) when only node-
negative cases were considered. SLPI, PAPPA and APOC1 levels
did not differ significantly for any of the pathological parameters
and there were no differences for any candidate markers in relation
to oestrogen receptor, progesterone receptor or triple negative
status. The best logistic regression models combining markers for
prognosis based on NPI gave AUCs of 0.67 (HSP90A, PAI-1 and
RANTES) considering all samples, and 0.77 (HSP90A, PAI-1 and
CA15-3), considering samples taken within 1.15 years of diagnosis.
Table 3. Comparison of cases and controls for candidate biomarkers according to stage, grade, node status, NPI and HER2 status
Stage Grade Node status NPI HER2 status
Marker Ctrl vs 1/2 Ctrl vs 3/4 Ctrl vs 1 Ctrl vs 2 Ctrl vs 3 Ctrl vs N0 Ctrl vs N1 Ctrl vs p4 Ctrl vs 44 Ctrl vs neg Ctrl vs pos
(A) All samples
CA15-3 NS 0.0215 0.0254 NS NS NS NS NS NS NS NS
RANTES NS NS NS NS NS NS NS NS NS NS NS
OPN NS NS NS NS NS NS NS NS NS NS NS
IGFBP3 NS NS NS NS NS NS NS NS NS NS NS
PAI-1 NS NS NS NS 0.0491 NS NS NS NS NS NS
HSP90A NS NS NS NS 0.0174 NS NS NS 0.0196 ns ns
SLPI NS NS NS NS NS NS NS NS NS NS NS
PAPPA NS NS NS NS NS NS NS NS NS NS NS
APOC1 NS NS NS NS NS NS NS NS NS NS NS
(B) o1.15 years to Dx
CA15-3 NS NS NS NS NS NS 0.0419 NS NS NS NS
RANTES NS NS NS NS NS NS NS NS NS NS NS
OPN NS NS NS NS NS NS NS NS NS NS NS
IGFBP3 NS NS NS NS NS NS NS NS NS NS NS
PAI-1 NS NS NS NS NS NS NS NS NS NS NS
HSP90A NS NS NS NS NS NS NS 0.0259 0.0419 NS NS
SLPI NS NS NS NS NS NS NS NS NS NS NS
PAPPA NS NS NS NS NS NS NS NS NS NS NS
APOC1 NS NS NS NS NS NS NS NS NS NS NS
(C) 41.15 years to Dx
CA15-3 NS NS 0.039 NS NS NS NS NS NS NS NS
RANTES NS NS NS NS NS NS NS NS NS NS NS
OPN NS NS NS NS NS NS NS NS NS NS NS
IGFBP3 NS NS NS NS NS NS 0.0447 NS NS NS NS
PAI-1 NS NS NS NS NS NS NS NS NS 0.0391 0.0364
HSP90A NS NS NS NS 0.0079 NS NS NS NS NS NS
SLPI NS NS NS NS NS NS NS NS NS NS NS
PAPPA NS NS NS NS NS NS NS NS NS NS NS
APOC1 NS NS NS NS NS NS NS NS NS NS NS
P-values for various comparisons are shown. Po0.05 was considered significant; NS denotes non-significance. Comparisons are shown for all pre-diagnosis case samples vs all controls (A),
between case samples taken o1.15 years to diagnosis (median) and all controls (B) and between case samples taken 41.15 years to diagnosis and all controls (C).
Table 2. Performance of logistic regression models of single and multiple candidate biomarkers according to time to diagnosis
Time group
(years)
Best single
marker
AUC of best
marker
Best combination
(powers for
9 parameters, i1:i9)
AUC of best
combination
P-value
for AUC
Sens for best
combination
(Spec40.95)
0–5 (All) HSP90A 0.529 ( 2; 2;  2; 2; 0; 1; 2; 2;  2) 0.56 0.224 0.096
0–1.15 SLPI 0.533 (1; 1; 2; 2; 0; 2; 2; 1; 2) 0.573 0.203 0.083
1.15–5 PAPPA 0.559 (1; 1;  1; 1; 2; 1; 1; 1;  1) 0.593 0.208 0.042
0–0.5 IGFBP3 0.605 (2; 1;  2; 2; 2;  2; 2; 2; 2) 0.686 0.047 0.179
0.5–1 APOC1 0.601 (0; 1; 2; 1; 1;  1; 2; 2; 2) 0.752 0.007 0.189
1–2 RANTES 0.572 ( 2; 2;  2; 2; 2;  1; 2; 1; 2) 0.675 0.08 0.14
2–3 RANTES 0.669 ( 2; 2;  1; 2; 1; 2; 2; 2; 1) 0.781 0.048 0.257
3–5 APOC1 0.685 ( 1; 2;  2; 2; 1; 1; 1; 2;  2) 0.785 0.06 0.216
Performances are indicated by area under the ROC curve (AUC). For the best combinations, powers are indicated for the formula: (IGFBP3)i1þ (RANTES)i2þ (OPN)i3þ (PAI-1)i4þ (SLPI)i5þ
(HSP90A)i6þ (APOC1)i7þ (PAPPA)i8þ (CA15-3)i9þ (Age).
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Although the AUCs for candidate markers were higher when
comparing controls with cases that had subsequently died of breast
cancer vs those that had not, a survival analysis indicated that none
of the markers were predictive of survival from breast cancer (data
not shown). However, this analysis is somewhat limited, as there
were only 17 of the 239 cases (7%) where the primary cause of
death was attributable to breast cancer (median time to death from
sample collection¼ 6.12 years; range 2.1–11.1 years).
DISCUSSION
Few studies have tested blood-borne candidate tumour markers for
early detection or prognosis in pre-diagnosis samples; the most
appropriate sample type for this kind of study. Here, we found that
none of the single marker candidates were effective at predicting
breast cancer, even close to diagnosis, and there was lack of
consistent changes in levels over time for any of the candidates.
Although combining the candidate markers improved the detec-
tion rat, no combined model performed with a sensitivity that
would be acceptable for use in screening. This is in agreement with
a previous study using a smaller set of pre-diagnostic samples
sourced from the Prospect-EPIC cohort (Opstal-van Winden et al,
2012). The authors reported that no marker combination (of 10
candidates, including CA15-3 and OPN) could accurately
discriminate early breast cancer cases from controls. Thus, novel
blood-borne biomarkers for the early detection of breast cancer for
use in screening still need to be found.
CA15-3 is perhaps the best known, non-invasive marker of
breast cancer, although its recommended clinical use is restricted
to monitoring of patients with metastatic disease during active
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Figure 1. Associations of biomarkers with histopathological features. Box and whisker plots showing associations of CA15-3 with tumour stage
(A); IGFBP3 with HER2 status in the o1.15 years to diagnosis group (B); PAI-1 with tumour grade (C); PAI-1 with NPI (D); HSP90A with tumour
grade (E); and HSP90A with NPI in the o1.15 years to diagnosis group (F).
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therapy (Harris et al, 2007). Herein, CA15-3 levels in serum taken
at a median time of 13.8 months before clinical diagnosis showed
consistency with respect to stage, grade and nodal status within
cases, although it failed to discriminate cases from controls. This
suggests that CA15-3 may serve as a pre-diagnostic marker of a
more aggressive tumour phenotype, in line with previous reports of
the prognostic value of CA15-3 in breast cancer (Ebeling et al,
2002; Gion et al, 2002; Shao et al, 2015). Raised pre-diagnostic
serum levels of the chemoattractant RANTES were also associated
with stage within cases, supporting previous observations of raised
plasma and tissue expression correlating with increasing stage
(Niwa et al, 2001). Notably however, this association was not
significant in cases where samples were taken closer to diagnosis,
suggesting RANTES is not a robust predictor of stage. Similarly,
stage-associated changes in serum OPN levels were not consistent,
and this bone adhesion molecule could not differentiate cases by
grade, node status or prognostic index. This supports previous
evidence that OPN is not a useful prognostic marker in early breast
cancer (Bramwell et al, 2014).
The fibrinolysis regulator protein PAI-1 has reported roles in
invasion, angiogenesis and metastasis with high levels in breast
tumour tissue having prognostic value and use in stratification,
particularly of node-negative breast cancer (Look et al, 2002; Duffy
et al, 2014). Few studies have assessed blood-borne PAI-1 as a
breast tumour marker, with one study reporting decreased serum
concentrations in cases vs non-cancer controls (Kim et al, 2009).
Herein, serum PAI-1 was reduced in women who went on to be
diagnosed with grade 3 breast cancer or who had a high prognostic
index, though it was unable to discriminate pre-diagnosis cases
from controls. Although this data supports serum PAI-1 as an early
prognostic factor, its direction of change is at odds with the raised
levels seen in tumour tissues. HSP90A is a chaperone protein for
several oncogenes (including HER2) and a pro-survival factor of
breast cancer cells. We showed lower levels of serum HSP90A in
women who went on to be diagnosed with high-grade cancers and
with higher prognostic index. High tissue expression of HSP90 has
been previously associated with increased HER2 and ER expres-
sion, large and high-grade tumours, node positivity and decreased
survival (Pick et al, 2007), although another study reported no
significant association between serum HSP90A levels and lesion
severity (Zagouri et al, 2011). These combined evidences suggest
that serum HSP90A may not make a good early prognostic marker,
although based on our findings, further investigation of its
potential is warranted. Finally, the serum level of the IGF1-binding
protein IGFBP3 was significantly lower in samples from HER2þ
cases taken within 1.15 years of diagnosis. This observation is in
accordance with our previous finding that HER2 overexpression
enhances IGF1 signalling via the down-regulation of IGFBP3
(Worthington et al, 2010). However, although increased serum
IGF1 levels have been associated with increased breast cancer risk,
no association with serum IGFBP3 levels was found (Key et al,
2010). Thus, IGFBP3 is a poor marker for predicting breast cancer,
although the relationship between HER2 and IGFBP3 expression
warrants further investigation.
CONCLUSIONS
The key strength of this study is that a well-characterised,
pre-diagnosis set of samples were investigated, allowing an
objective assessment of nine candidate serological markers for
the early detection and prognostication of breast cancer.
One weakness of the study is that more detailed information on
the molecular sub-type of the tumours was not available (excepting
receptor status), so future studies should address in more detail the
possible effect of molecular sub-type on candidate biomarker
levels, as recently reported for CA15-3 (Shao et al, 2015). We
conclude that CA15-3, PAI-1 and HSP90A have potential as
prognostic markers in the pre-diagnosis setting. The next phase of
this work would be to validate these candidate biomarkers in a
larger independent set of case–control samples sourced from the
UKCTOCS with data linked to mammography findings, treatment
and survival information for these women. Serial samples from
breast cancer cases and matched controls would be used from the
multimodal arm of the UKCTOCS, permitting assessment of
longitudinal changes in these candidate biomarkers during tumour
progression. We envisage, that if validated, these markers could be
used as a second line test to mammography to identify tumours of
poorer prognosis and thereby allow stratification for treatment.
Whether or not such testing would have an impact on survival
Table 4. Analysis of candidate biomarkers within cases according to stage, grade, node status, NPI and HER2 status
Stage Grade Node status NPI HER2 status
Marker 1 vs 2 1 vs 3/4 2 vs 3/4 1 vs 2 1 vs 3 2 vs 3 N1 vs N0 p4 vs 44 Pos vs neg
(A) All samples
CA15-3 NS 0.0001 0.0024 0.0078 NS NS 0.036 NS NS
RANTES 0.0232 0.0183 NS NS NS NS NS NS NS
OPN NS NS 0.0381 NS NS NS NS NS NS
IGFBP3 NS NS NS NS NS NS NS NS NS
PAI-1 NS NS NS NS NS 0.0405 NS 0.0384 NS
HSP90A NS NS NS NS NS NS NS 0.0062 NS
SLPI NS NS NS NS NS NS NS NS NS
PAPPA NS NS NS NS NS NS NS NS NS
APOC1 NS NS NS NS NS NS NS NS NS
(B) o1.15 years to Dx
CA15-3 NS 0.0049 0.032 NS NS NS 0.0368 NS NS
RANTES NS NS NS NS NS NS NS NS NS
OPN 0.0245 NS 0.0052 NS NS NS NS NS NS
IGFBP3 NS NS NS NS NS NS NS NS 0.0037
PAI-1 NS NS NS NS NS NS NS 0.0331 NS
HSP90A NS NS NS NS 0.0073 NS NS 0.0003 NS
SLPI NS NS NS NS NS NS NS NS NS
PAPPA NS NS NS NS NS NS NS NS NS
APOC1 NS NS NS NS NS NS NS NS NS
P-values are shown for comparisons within all pre-diagnosis case samples for the pathological features (A) and within case samples takeno1.15 years to diagnosis (B). Po0.05 was considered
significant; NS denotes non-significance.
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would need to be assessed in a prospective clinical trial. We also
conclude that CA15-3, RANTES, IGFBP3, OPN, PAI-1, SLPI,
HSP90A, PAPPA and APOC1 alone, or in combination, cannot be
used for accurate prediction of breast cancer and therefore would
be of no use in screening. Despite this, our work lays the
groundwork for building and assessing longitudinal biomarker
algorithms that may give an improvement in performance, such as
the Risk of Ovarian Cancer Algorithm used within the UKCTOCS
(Menon et al, 2015).
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